{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:36:46Z","timestamp":1789875406431,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.ajog.2011.06.057","type":"journal-article","created":{"date-parts":[[2011,9,29]],"date-time":"2011-09-29T18:25:43Z","timestamp":1317320743000},"page":"S9-S13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"S","title":["The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives"],"prefix":"10.1016","volume":"205","author":[{"given":"Lee P.","family":"Shulman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.ajog.2011.06.057_bib1","first-page":"S103","article-title":"Hormonal contraception: recent advances and controversies","volume":"90","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2011.06.057_bib2","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/AOG.0b013e31818425b7","article-title":"Hormonal contraception","volume":"112","author":"Blumenthal","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2011.06.057_bib3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/bmj.39289.649410.55","article-title":"Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study","volume":"335","author":"Hannaford","year":"2007","journal-title":"BMJ"},{"issue":"Suppl","key":"10.1016\/j.ajog.2011.06.057_bib4","first-page":"729","article-title":"YAZ in the treatment of premenstrual dysphoric disorder","volume":"53","author":"Rapkin","year":"2008","journal-title":"J Reprod Med"},{"key":"10.1016\/j.ajog.2011.06.057_bib5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1517\/14656561003724713","article-title":"Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest","volume":"11","author":"Jensen","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ajog.2011.06.057_bib6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.contraception.2009.09.009","article-title":"Perceptions of the safety of oral contraceptives among a predominantly Latina population in Texas","volume":"81","author":"Grossman","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2011.06.057_bib7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2307\/1966452","article-title":"Does choice make a difference to contraceptive use?","volume":"22","author":"Pariani","year":"1991","journal-title":"Stud Fam Plann"},{"key":"10.1016\/j.ajog.2011.06.057_bib8","series-title":"NuvaRing [package insert]","year":"2008"},{"key":"10.1016\/j.ajog.2011.06.057_bib9","series-title":"Ortho Evra [package insert]","year":"2010"},{"key":"10.1016\/j.ajog.2011.06.057_bib10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1067\/mob.2002.121103","article-title":"Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel\/ethinyl estradiol","volume":"186","author":"Bjarnadottir","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2011.06.057_bib11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003088-200039030-00005","article-title":"Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring","volume":"39","author":"Timmer","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ajog.2011.06.057_bib12","first-page":"585","article-title":"Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring","volume":"100","author":"Dieben","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2011.06.057_bib13","series-title":"Ortho Evra [package insert]","year":"2010"},{"issue":"Suppl 2","key":"10.1016\/j.ajog.2011.06.057_bib14","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0015-0282(01)03275-7","article-title":"Contraceptive efficacy and cycle control with the Ortho Evra\/Evra transdermal system: the analysis of pooled data","volume":"77","author":"Zieman","year":"2002","journal-title":"Fertil Steril"},{"issue":"Suppl 2","key":"10.1016\/j.ajog.2011.06.057_bib15","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0015-0282(01)03263-0","article-title":"Assessment of compliance with a weekly contraceptive patch (Ortho Evra\/Evra) among North American women","volume":"77","author":"Archer","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2011.06.057_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.contraception.2005.03.005","article-title":"Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive","volume":"72","author":"van den Heuvel","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2011.06.057_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.contraception.2006.01.001","article-title":"Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol","volume":"73","author":"Jick","year":"2006","journal-title":"Contraception"},{"issue":"Pt 1","key":"10.1016\/j.ajog.2011.06.057_bib18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.AOG.0000250968.82370.04","article-title":"Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users","volume":"109","author":"Cole","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2011.06.057_bib19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.contraception.2009.07.004","article-title":"Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism","volume":"81","author":"Jick","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2011.06.057_bib20","series-title":"Contraceptive technology","author":"Hatcher","year":"2008"},{"issue":"Pt 1","key":"10.1016\/j.ajog.2011.06.057_bib21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0002-9378(98)70047-X","article-title":"Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons","volume":"179","author":"Rosenberg","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2011.06.057_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mce.2003.10.030","article-title":"Drospirenone, a progestogen with antimineralocorticoid properties: a short review","volume":"217","author":"Oelkers","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ajog.2011.06.057_bib23","year":"2010"},{"key":"10.1016\/j.ajog.2011.06.057_bib24","year":"2010"},{"key":"10.1016\/j.ajog.2011.06.057_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2011.06.057_bib26","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/01.AOG.0000279448.62221.a8","article-title":"Risk of thromboembolism in women taking ethinylestradiol\/drospirenone and other oral contraceptives","volume":"110","author":"Seeger","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2011.06.057_bib27","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2011.06.057_bib28","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2011.06.057_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0015-0282(99)00205-8","article-title":"Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity","volume":"72","author":"Sullivan","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2011.06.057_bib30","first-page":"261","article-title":"Hormone withdrawal symptoms in oral contraceptive users","volume":"95","author":"Sulak","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2011.06.057_bib31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.contraception.2004.12.012","article-title":"Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations","volume":"71","author":"Mishell","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2011.06.057_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0010-7824(96)00137-0","article-title":"Shorter pill-free interval in combined oral contraceptives decreases follicular development","volume":"54","author":"Spona","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2011.06.057_bib33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0015-0282(00)01747-7","article-title":"The emerging use of the 20-microg oral contraceptive","volume":"75","author":"Poindexter","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2011.06.057_bib34","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.contraception.2009.03.018","article-title":"Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate\/dienogest and ethinyl estradiol\/levonorgestrel","volume":"80","author":"Ahrendt","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2011.06.057_bib35","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.contraception.2008.05.004","article-title":"Ovulation inhibition with four variations of a four-phasic estradiol valerate\/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies","volume":"78","author":"Endrikat","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2011.06.057_bib36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/13625187.2010.504313","article-title":"Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17\u03b2-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol","volume":"15","author":"Duijkers","year":"2010","journal-title":"Eur J Contracept Reprod Health Care"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937811007927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937811007927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:32:06Z","timestamp":1762079526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937811007927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0002937811007927"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2011.06.057","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2011.06.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}